The Cancer Medicines Committee is committed to improving access to affordable medicines for patients with cancer worldwide.
Access to cancer medicines is a crucial issue for medical oncologists because it affects their daily practice and ability to treat patients according to the evidence-based ESMO Clinical Practice Guidelines. The Cancer Medicines Committee works to address the topic of access to medicines at the European and global policy levels to ensure that all patients have access to the medicines they need, when they need them.
Activities and Responsibilities
- Improving the level of involvement and expertise of oncologists on the issue of access to medicines.
- Developing tools and resources that can support countries in achieving sustainable cancer care.
- Raising awareness on the issues related to the availability and accessibility of cancer medicines, technologies and the legitimate medical use of opioids for pain management
- Conducting research to assess the availability and accessibility of cancer medicines and technologies in Europe and globally
Structure
- The ESMO-MCBS Working Group (WG) reports to the Cancer Medicines Committee
- The Chair of the ESMO-MCBS WG is an ex officio position within the Cancer Medicines Committee
Chair
- Dario Trapani, Italy
Committee Members
- Arnaud Bayle, France
- Nathan I. Cherny, Israel
- Urania Dafni, Greece
- Elisabeth G.E. de Vries, Netherlands
- William Kenneth Evans, Canada
- Daniel Goldstein, Israel
- Sjoukje Oosting, Netherlands
- Manju Sengar, India
- Josep Tabernero, Spain
- Kerstin Noëlle Vokinger, Switzerland
Extended Committee Members
- Sara Altuna, Venezuela
- Jacques Bezuidenhout, Belgium
- Mariana Brandao, Belgium
- Luis Castelo-Branco, Portugal
- Khalid El Bairi, Morocco
- Paula Gimena Franco, Philippines
- Annie Ngai Man Wong, New Zealand
- Safi Mohammed, China
- Navneet Singh, India
- Yüksel Ürün, Türkiye
Last update: September 2024